Taking account of future technology in cost effectiveness analysis

被引：24

作者：

Salomon, JA

Weinstein, MC

Goldie, SJ

机构：

[1] Harvard Univ, Sch Publ Hlth, Harvard Ctr Populat & Dev Studies, Dept Populat & Int Hlth, Cambridge, MA 02138 USA

[2] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2004年 / 329卷 / 7468期

关键词：

D O I：

10.1136/bmj.329.7468.733

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Economic evaluations in health and medicine usually ignore the possibility of future advances in treatment But when technological innovation is rapid such considerations can have major implications.

引用

页码：733 / 736

页数：6

共 29 条

[1] Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome [J].

Alter, HJ ;

Seeff, LB .

SEMINARS IN LIVER DISEASE, 2000, 20 (01) :17-35

[2] The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].

Alter, MJ ;

Kruszon-Moran, D ;

Nainan, OV ;

McQuillan, GM ;

Gao, FX ;

Moyer, LA ;

Kaslow, RA ;

Margolis, HS .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562

[3]

[Anonymous], 2007, Economic evaluation in health care merging theory with practice

[4]

BEDOSSA P, 1994, HEPATOLOGY, V20, P15

[5] Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C [J].

Bennett, WG ;

Inoue, Y ;

Beck, JR ;

Wong, JB ;

Pauker, SG ;

Davis, GL .

ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) :855-+

[6] The 'NICE' approach to technology assessment: An economics perspective [J].

Birch S. ;

Gafni A. .

Health Care Management Science, 2004, 7 (1) :35-41

[7] An introduction to Markov modelling for economic evaluation [J].

Briggs, A ;

Sculpher, M .

PHARMACOECONOMICS, 1998, 13 (04) :397-409

[8] Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C [J].

Buti, M ;

Casado, MA ;

Fosbrook, L ;

Wong, JB ;

Esteban, R .

JOURNAL OF HEPATOLOGY, 2000, 33 (04) :651-658

[9] A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C [J].

Buti, M ;

Medina, M ;

Casado, MA ;

Wong, JB ;

Fosbrook, L ;

Esteban, R .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (05) :687-694

[10]

Dusheiko GM, 1995, HEPATOLOGY, V22, P1863, DOI 10.1016/0270-9139(95)90216-3

← 1 2 3 →